Genomma Lab Internacional Announces Q2 2025 Results
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B), is excited to share its results for the second quarter of 2025. The company has made significant strides in its financial performance, showcasing both growth and resilience against prevailing economic challenges.
Key Financial Metrics
In our recent financial update, we observed a commendable increase in net sales, which grew by 0.5%. When we exclude the impact of Argentina, the sales growth jumps to 5.5%. This performance highlights our strong recovery and adaptability, even in the face of an 18.3% depreciation of the Argentine peso and a sluggish beverage season in our Mexican operations.
EBITDA Growth
Our EBITDA reached a margin of 23.8%, marking a substantial increase of 4.4%. This improvement can be attributed to effective cost management, an advantageous sales mix, and successful productivity initiatives implemented across the board. Our team’s dedication to maintaining high standards has enabled this remarkable result.
Profitability Insights
Despite the robust EBITDA growth, net income witnessed a decline of 43.8%. This decrease was primarily influenced by substantial non-cash foreign exchange losses and inflationary effects stemming from our monetary position in a hyperinflationary environment. However, amid these challenges, our proforma net income, excluding these non-cash effects, surged by 16.6%. This reflects our strong operational performance and effective management strategies during turbulent times.
Overview of Financial Performance
The summary of our Q2 2025 financial performance is notably impressive:
- Net Sales: 4,676.4 million pesos
- Gross Profit: 2,969.4 million pesos, representing a gross margin of 63.5%
- Operating Income: 1,030.6 million pesos, at a margin of 22.0%
- EBITDA: 1,112.9 million pesos, demonstrating a remarkable growth of 4.4%
- Proforma Net Income: 667.8 million pesos
- Proforma EPS: Ps. 0.67
Upcoming Conference Call
Genomma Lab will hold a conference call to discuss these results further:
Date: Thursday
Time: 1:00 p.m. ET | 11:00 a.m. Mexico City Time
Participants will include Marco Sparvieri, CEO; Antonio Zamora, CFO; and Christianne Ibanez, IRO.
Market Coverage and Analyst Insights
As of now, "LAB B" receives coverage from nine sell-side analysts representing notable brokerages. Their insights provide a comprehensive understanding of our market position and future growth potential.
About Genomma Lab Internacional
Genomma Lab Internacional, S.A.B. de C.V. is among the premier pharmaceutical and personal care product companies in the region, expanding its footprint internationally. Our product portfolio features a variety of premium brands that lead in sales and market share across multiple categories. Through effective marketing, innovative product development, and a flexible operating model, Genomma Lab continues to position itself as a market leader.
Frequently Asked Questions
What were Genomma Lab's sales growth percentages for Q2 2025?
Genomma Lab's sales grew by 0.5%, or 5.5% excluding Argentina.
How did EBITDA change in Q2 2025?
EBITDA reached a margin of 23.8%, reflecting a 4.4% increase.
What challenges did the company face during this quarter?
The company faced challenges including foreign exchange losses and inflationary impacts affecting net income.
When is the next earnings call?
The next conference call is scheduled for Thursday at 1:00 p.m. ET.
What is the proforma EPS for Q2 2025?
The proforma EPS is Ps. 0.67, showcasing a 16.6% increase compared to the previous period.
